Rocket Pharmaceuticals Investors Sue Over Alleged Misleading Statements

Strategic Insights -

Shareholders of Rocket Pharmaceuticals, Inc. (RCKT) who purchased stock between February 27 and May 26, 2025, are being represented by a securities class action lawsuit filed in the United States District Court for the District of New Jersey. The suit alleges that the company misled investors about the safety and progress of its critical RP-A501 gene therapy trial for Danon disease. The clinical trial was put on hold by the FDA on May 27, 2025, after a patient experienced a Serious Adverse Event (SAE) and later died. The lawsuit claims that Rocket Pharmaceuticals failed to disclose significant protocol changes and known risks of SAEs to investors, artificially inflating the stock price and causing heavy losses when the information became public.

Key Takeaways:

  • The lawsuit centers on Rocket Pharmaceuticals' disclosures about the trial protocol and safety of its RP-A501 Phase 2 trial, which was put on hold by the FDA due to a patient's SAE and subsequent death.
  • The company allegedly made false and misleading statements regarding the safety, efficacy, and clinical protocol of the trial, while privately knowing about significant protocol changes and risks of SAEs.
  • The stock price plummeted 75% from its February 27, 2025 closing price, with the company's shares losing 62% of their value in a single day after the FDA placed a clinical hold on the trial.
  • Shareholders who purchased Rocket stock between February 27, 2025 and May 26, 2025, are being represented by the class action lawsuit.
  • The deadline to seek lead plaintiff status is August 11, 2025.
  • Hagens Berman is investigating claims that Rocket Pharmaceuticals may have misled investors about its Phase 2 protocol and is seeking assistance from whistleblowers.

Statistics:

  • 62%: The amount by which the stock price of Rocket Pharmaceuticals fell in a single day on May 27, 2025, after the FDA placed a clinical hold on the RP-A501 trial.
  • 75%: The amount by which the stock price of Rocket Pharmaceuticals fell from its February 27, 2025 closing price.
  • May 27, 2025: The date on which Rocket Pharmaceuticals revealed that the FDA had placed a clinical hold on the RP-A501 trial due to a patient's SAE and subsequent death.
  • February 27, 2025 - May 26, 2025: The class period during which shareholders purchased Rocket stock.

Sources:

  • [Newsfile Corp. - July 29, 2025, "RCKT Investors with Losses Encouraged to Contact Hagens Berman Before Aug. 11th Deadline"]
  • [U.S. District Court for the District of New Jersey, Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049]